Eikon Therapeutics filings document its transition to a Nasdaq-listed public company, its common stock registration, governance documents, financial results, and clinical and corporate updates. The company’s Form 8-K disclosures include results of operations and financial condition, exhibits containing press releases, and amendments to its certificate of incorporation and bylaws in connection with its initial public offering.
The filings also identify Eikon’s common stock, par value, trading symbol, Nasdaq listing, and public-company governance framework. For this clinical-stage biopharmaceutical issuer, regulatory disclosures center on capital structure, shareholder matters, clinical program updates, and corporate reporting obligations.
FMR LLC and Abigail P. Johnson report a significant ownership position in Eikon Therapeutics Inc. common stock on an amended Schedule 13G. FMR LLC beneficially owns 4,993,906 shares of common stock, representing 9.2% of the outstanding class.
FMR LLC has sole voting power over 4,992,603 shares and sole dispositive power over 4,993,906 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over the same 4,993,906 shares, but no voting power. One or more other persons may receive dividends or sale proceeds related to these shares, but no other person holds an interest exceeding five percent of the class.
Eikon Therapeutics, Inc. reported that board members Leon Chen, Ph.D. and Joshua Wolfe resigned from its Board of Directors, effective July 31, 2026. The company states that their resignations were not due to any disagreement regarding operations, policies, or practices.
Eikon Therapeutics is a Delaware corporation whose common stock, par value $0.0001 per share, trades on The Nasdaq Stock Market LLC under the symbol EIKN. The report documenting these director changes is signed by Chief Financial Officer Alfred Bowie, Ph.D., on August 3, 2026.
Eikon Therapeutics director Francisco Ma. Fatima reported an initial holding of a stock option covering 85,937 shares of Common Stock. The option has an exercise price of $8.9600 per share and expires on June 4, 2036. According to the vesting terms, 1/48th of the underlying shares vest each month over 48 months, conditioned on continued service.
Eikon Therapeutics, Inc. has appointed Ma. Fatima D. Francisco to its Board of Directors as a Class I director, effective June 15, 2026. She will serve until the company’s 2027 annual stockholder meeting, and will initially sit on the Board’s Compensation Committee.
Under the 2026 non-employee director compensation program, Ms. Francisco will receive an annual cash retainer of $50,000, paid quarterly, and an option to purchase 85,937 shares of common stock at an exercise price of $8.96 per share. The option vests in 48 equal monthly installments, contingent on her continued Board service, and she has signed the company’s standard indemnification agreement.
Eikon Therapeutics filed a current report highlighting new clinical data and an updated corporate presentation. The company presented results from its Phase 2 TeLuRide-005 trial of EIK1001 in first-line stage 4 non-small cell lung cancer and its Phase 1/2 EIK1003 program in advanced solid tumors at the 2026 ASCO meeting.
In NSCLC, EIK1001 plus pembrolizumab and chemotherapy showed a 63.1% objective response rate and 90.8% disease control rate across 65 efficacy-evaluable patients, with the non-squamous cohort reaching a median duration of response greater than 11 months. EIK1003, a highly selective PARP1 inhibitor, produced objective responses both as monotherapy and in combination with weekly paclitaxel, with safety profiles described as generally consistent with expected toxicities and no treatment-related deaths reported.
Eikon Therapeutics, Inc. disclosure shows Innovation Endeavors reporting persons collectively beneficially owned 3,369,519 shares of common stock, representing 6.2% of outstanding shares as of March 31, 2026.
The holdings break down as IE III LP 2,723,226 shares, IE IV LP 498,474 shares, and IE ET SPV 147,819 shares. The filing states shared voting and dispositive power over these holdings and cites 54,138,555 shares outstanding as of March 17, 2026 from the company’s Form 10-K.
Eikon Therapeutics, Inc. disclosure: Roger M. Perlmutter reports beneficial ownership of 2,893,171 shares of Common Stock, representing 5.2% of the class based on 54,138,555 shares outstanding as of March 17, 2026. The position combines 1,190,999 shares held directly, 1,417,315 options exercisable within 60 days of March 31, 2026, and 284,857 shares held by Perlmutter Consulting, Inc.
The filing attributes sole voting and dispositive power over the reported shares to Dr. Perlmutter. The statement is a standard beneficial‑ownership disclosure under Schedule 13G and does not state any transactions or changes in proceeds.
Eikon Therapeutics, Inc. reported a quarterly net loss attributable to common stockholders of $82.9 million for the three months ended March 31, 2026, reflecting heavy investment in its drug pipeline. Research and development expenses were $70.0 million and general and administrative costs were $17.3 million, driving total operating expenses to $87.3 million.
During the quarter, Eikon completed its initial public offering at $18.00 per share, issuing 21.2 million shares for approximately $348.1 million in net proceeds, and converting all series of redeemable convertible preferred stock into 29.9 million common shares. As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $596.0 million, and the company believes this will fund operations for at least one year. Stockholders’ equity turned positive to $550.7 million, with an accumulated deficit of about $1.0 billion, and 54.1 million common shares were outstanding as of May 1, 2026.
Eikon Therapeutics reported first quarter 2026 results and detailed progress across its oncology pipeline. The company ended March 31, 2026 with $596 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the second half of 2027.
R&D expenses rose to $70.0 million from $56.6 million, reflecting accelerating clinical trial activity and a $5.0 million milestone for advancing PARP1 inhibitor EIK1003 into Phase 2. G&A expenses increased to $17.3 million from $14.8 million, and net loss attributable to common stockholders widened to $83.0 million from $74.5 million. Eikon highlighted three priority programs—TLR7/8 agonist EIK1001, PARP1 inhibitor EIK1003, and WRN helicase inhibitor EIK1005—with multiple Phase 1/2 and Phase 2/3 trials and six ASCO 2026 abstracts accepted, underscoring growing clinical data across melanoma, lung, breast, ovarian, prostate, pancreatic, and MSI‑high tumors.
EIKON THERAPEUTICS INC reported that FMR LLC beneficially owned 3,836,830 shares of Common Stock, representing 7.1% of the class as of 03/31/2026. The filing lists FMR LLC's sole dispositive power over 3,836,830 shares and discloses that other persons may have rights to dividends or sale proceeds but no other person holds more than 5%.
The report was signed under power of attorney and references an attached 13d-1(k) agreement in Exhibit 99.